Skip to main content

Table 3 Grade ≥ 3 adverse events

From: Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

Grade ≥ 3 adverse events2019 Royal Marsden % (n = 50) (%)2017 study
(n = 28) (%)
2013 GRID study
(n = 132) (%)
All grade ≥ 3 AEs23 (46)12 (42.9)81 (61.4)
PPE9 (18)5 (17.9)26 (19.7)
Fatigue7 (14)5 (17.9)3 (2.3)
Hypertension4 (8)2 (7.1)31 (23.5)
Hepatotoxicity1 (2)0 (0)1 (0.8)
Diarrhoea1 (2)2 (7.1)7 (5.3)
Arthralgia1 (2)0 (0)1 (1%)